1. Home
  2. AUUD vs OGEN Comparison

AUUD vs OGEN Comparison

Compare AUUD & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Auddia Inc.

AUUD

Auddia Inc.

HOLD

Current Price

$1.85

Market Cap

2.6M

Sector

Technology

ML Signal

HOLD

Logo Oragenics Inc.

OGEN

Oragenics Inc.

HOLD

Current Price

$0.62

Market Cap

2.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AUUD
OGEN
Founded
2012
1996
Country
United States
United States
Employees
5
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6M
2.7M
IPO Year
N/A
2010

Fundamental Metrics

Financial Performance
Metric
AUUD
OGEN
Price
$1.85
$0.62
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
2.6M
47.5K
Earning Date
05-11-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.51
$0.11
52 Week High
$10.10
$9.16

Technical Indicators

Market Signals
Indicator
AUUD
OGEN
Relative Strength Index (RSI) 47.18 44.50
Support Level $0.74 N/A
Resistance Level $1.95 $0.66
Average True Range (ATR) 0.20 0.04
MACD -0.08 -0.00
Stochastic Oscillator 64.29 37.07

Price Performance

Historical Comparison
AUUD
OGEN

About AUUD Auddia Inc.

Auddia Inc is a United States-based company. It operates through its proprietary AI platform for audio and is reinventing not only how consumers engage with AM/FM radio, podcasts, and other audio content but also how artists and labels promote their music and gain access to mainstream radio audiences. The group Discovr Radio is the first music-promotion platform to deliver artists guaranteed exposure to radio listeners. Its flagship audio superapp, called faidr, delivers multiple industry firsts, including: Ad-free listening on any AM/FM radio station, Content skipping across any AM/FM station, One-touch skipping of entire podcast ad breaks, and Integrated artist discovery experiences.

About OGEN Oragenics Inc.

Oragenics Inc is a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases. The Company is currently focused on advancing the development and commercialization of its product candidate, ONP-002. ONP-002 is a fully synthetic, non-naturally occurring neurosteroid that is lipophilic and is designed to cross the blood-brain barrier, with the goal of reducing swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The Company's primary focus is on the development and commercialization of ONP-002 for the treatment of mild traumatic brain injury (mTBI), or concussion.

Share on Social Networks: